Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Competing risk"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Lung and Thoracic cancer
Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer
Tae Hoon Lee, Joo-Hyun Chung, Hong-Gyun Wu, Suzy Kim, Joo Ho Lee, Bhumsuk Keam, Jin-Soo Kim, Ki Hwan Kim, Byoung Hyuck Kim, Hak Jae Kim
Cancer Res Treat. 2023;55(3):875-884.   Published online February 24, 2023
DOI: https://doi.org/10.4143/crt.2022.1583
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to evaluate the effectiveness of prophylactic cranial irradiation (PCI) for “early brain metastasis”, which occurs before extracranial recurrence (ECR), and “late brain metastasis”, which occurs after ECR, in limited-stage small cell lung cancer (LS-SCLC).
Materials and Methods
We retrospectively analyzed 271 LS-SCLC patients who underwent definitive chemoradiation. All patients were initially staged with brain magnetic resonance imaging and positron emission tomography. Intracranial recurrence (ICR), ECR, progression-free rate (PFR), and overall survival (OS) were analyzed as clinical endpoints. The competing risk of the first recurrence with ICR (ICRfirst) was evaluated. Significantly associated variables in multivariate analysis of ECR were considered as ECR risk factors. Patients were stratified according to the number of ECR risk factors.
Results
The application of PCI was associated with higher PFR (p=0.008) and OS (p=0.045). However, PCI was not associated with any of the clinical endpoints in multivariate analysis. The competing risk of ICRfirst was significantly decreased with the application of PCI (hazard ratio, 0.476; 95% confidence interval, 0.243 to 0.931; p=0.030). Stage III disease, sequential, and stable disease after thoracic radiation were selected as ECR risk factors. For patients without these risk factors, the application of PCI was significantly associated with increased OS (p=0.048) and a decreased risk of ICRfirst (p=0.026).
Conclusion
PCI may play a role in preventing early brain metastasis rather than late brain metastasis after ECR, suggesting that only patients with a low risk of ECR may currently benefit from PCI.

Citations

Citations to this article as recorded by  
  • Efficacy evaluation of prophylactic cranial irradiation for limited stage small‑cell lung cancer in the magnetic resonance imaging era: A meta‑analysis
    Lihua Shao, Yumei Dong, Meiqiao Jiang, Haixia Song, Yuexiao Qi, Liyun Guo, Jinhui Tian, Shihong Wei
    Oncology Letters.2025;[Epub]     CrossRef
  • 3,586 View
  • 141 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Head and Neck cancer
Long-term Survivorship and Non-cancer Competing Mortality in Head and Neck Cancer: A Nationwide Population-Based Study in South Korea
Yuh-Seog Jung, Dahhay Lee, Kyu-Won Jung, Hyunsoon Cho
Cancer Res Treat. 2023;55(1):50-60.   Published online March 4, 2022
DOI: https://doi.org/10.4143/crt.2021.1086
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
As the survival of head and neck cancer (HNC) improves, survivors increasingly confront non-cancer–related deaths. This nationwide population-based study aimed to investigate non-cancer–related deaths in HNC survivors.
Materials and Methods
Data from the Korean Central Cancer Registry were obtained to characterize causes of death, mortality patterns, and survival in patients with HNC between 2006 and 2016 (n=40,890). Non-cancer-related mortality relative to the general population was evaluated using standardized mortality ratios (SMRs). The 5- and 10-year cause-specific competing risks probabilities of death (cumulative incidence function, CIF) and subdistribution hazards ratios (sHR) from the Fine-Gray models were estimated.
Results
Comorbidity-related mortality was frequent in older patients, whereas suicide was predominant in younger patients. The risk of suicide was greater in patients with HNC than in the general population (SMR, 3.1; 95% confidence interval [CI], 2.7 to 3.5). The probability of HNC deaths reached a plateau at 5 years (5-year CIF, 33.9%; 10-year CIF, 39.5%), whereas the probability of non-HNC deaths showed a long-term linear increase (5-year, CIF 5.6%; 10-year CIF, 11.9%). Patients who were male (sHR, 1.56; 95% CI, 1.41 to 1.72), diagnosed with early-stage HNC (localized vs. distant: sHR, 1.86; 95% CI, 1.58 to 2.21) and older age (65-74 vs. 0-44: sHR, 6.20; 95% CI, 4.92 to 7.82; ≥ 75 vs. 0-44: sHR, 9.81; 95% CI, 7.76 to 12.39) had an increased risk of non-cancer mortality.
Conclusion
Non-HNC–related deaths continue increasing. HNC survivors are at increased risk of suicide in the younger and comorbidity-related death in the older. Better population-specific surveillance awareness and survivorship plans for HNC survivors are warranted.

Citations

Citations to this article as recorded by  
  • Surviving and thriving: Assessing quality of life and psychosocial interventions in mental health of head and neck cancer patients
    Liqing Lin, Hao Lin, Renbin Zhou, Bing Liu, Kaige Liu, Ronghua Jiang
    Asian Journal of Surgery.2024;[Epub]     CrossRef
  • Time‐varying association of second primary malignancy and long‐term survival outcomes in patients with head and neck cancer
    Xiaoke Zhu, Yu Heng, Jian Zhou, Hanqing Lin, Liang Zhou, Ming Zhang, Pengyu Cao, Lei Tao
    International Journal of Cancer.2023; 153(1): 94.     CrossRef
  • 5,206 View
  • 156 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score–Adjusted, Population-Based Study
Caijin Lin, Jiayi Wu, Shuning Ding, Chihwan Goh, Lisa Andriani, Kunwei Shen, Li Zhu
Cancer Res Treat. 2020;52(2):552-562.   Published online November 18, 2019
DOI: https://doi.org/10.4143/crt.2019.210
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Despite the rapid growing of cancer survivors, prior cancer history is a commonly adopted exclusion criterion. Whether prior cancer will impact the survival of patients with advanced breast cancer (ABC) remains uncertain.
Materials and Methods
Patients with ABC diagnosed between 2004 and 2010 were identified using Surveillance, Epidemiology, and End Results (SEER) database. Timing, stage, and type were used to characterize prior cancer. Multivariable analyses using propensity score–adjusted Cox regression and competing risk regression were conducted to evaluate the prognostic effect of prior cancer on overall survival (OS) and breast cancer-specific survival (BCSS).
Results
A total of 14,176 ABC patients were identified, of whom 10.5% carried a prior cancer history. The most common type of prior cancer was female genital cancer (32.4%); more than half (51.7%) were diagnosed at localized stage; most were diagnosed more than 5 years (42.9%) or less than 1 year (28.3%) prior to the index cancer. In multivariate analyses, patients with prior cancer presented a slightly worse OS (hazard ratio, 1.18; 95% confidence interval [CI], 1.07 to 1.30; p=0.001) but a better BCSS (subdistribution hazard ratio, 0.64; 95% CI, 0.56 to 0.74; p < 0.001). In subset analyses, no survival detriment was observed in patients with prior malignancy from head and neck or endocrine system, at in situ or localized stage, or diagnosed more than 4 years.
Conclusion
Prior cancer provides an inferior OS but a superior BCSS for patients with ABC. It does not affect the survival adversely in some subgroups and these patients should not be excluded from clinical trials.

Citations

Citations to this article as recorded by  
  • Impact of childhood/adolescent cancer history on prognosis in parotid mucoepidermoid carcinoma
    Hefeng Gu, Sunyi Tu, Lan Ma, Kuiwei Su, Yeqing Zhou
    British Journal of Oral and Maxillofacial Surgery.2024; 62(7): 612.     CrossRef
  • Medical history of thyroid cancer does not impair prognosis in non-metastatic breast cancer patients: an analysis study based on SEER database and external cohort
    Shuai Li, Xiaosong Chen, Kunwei Shen
    Frontiers in Oncology.2024;[Epub]     CrossRef
  • Clinical characteristics and prostate-cancer-specific mortality of competitive risk nomogram in the second primary prostate cancer
    Chaojie Xu, Dongchen Pei, Yi Liu, Jianhua Guo, Nan Liu, Qian Wang, Yang Yu, Zhengjun Kang
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • The Impact of a History of Different Other Cancers on the Long-Term Outcomes of Patients with Gallbladder Cancer: A Propensity Score–Adjusted, Population-Based Study
    Jing Wang, Chan Zhang, Dong Yan
    Technology in Cancer Research & Treatment.2023;[Epub]     CrossRef
  • Second primary malignancies in oral tongue cancer: A Surveillance, Epidemiology, and End Result–based analysis evaluating the basic characteristics, survival outcomes, and predictive factors
    Zicheng Xu, Jianxing Wang, Hongzhou Cai, Feng Qi, Qing Zou
    Precision Medical Sciences.2022; 11(1): 4.     CrossRef
  • Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study
    Jiayue Ye, Sheng Hu, Wenxiong Zhang, Deyuan Zhang, Yang Zhang, Dongliang Yu, Jinhua Peng, Jianjun Xu, Yiping Wei
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • [Retracted] Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer
    Weixun Lin, Yaokun Chen, Zeqi Ji, Lingzhi Chen, Jinyao Wu, Yexi Chen, Zhiyang Li, Nauman Rahim Khan
    BioMed Research International.2022;[Epub]     CrossRef
  • Association between a prior cancer history and prognosis in adult patients with high‑grade glioma
    Dongjie He, Peiwen Wu, Gaiyan Li, Siying Zhu, Qiming Wang, Qiuju Shao, Hao Chang
    Journal of Clinical Neuroscience.2022; 106: 20.     CrossRef
  • Impact of prior cancer history on survival of patients with gastric cancer
    Li Wen, Kun Yu, Hongjiang Lu, Guansheng Zhong
    European Journal of Surgical Oncology.2021; 47(9): 2286.     CrossRef
  • Effect of prior cancer on survival outcomes for patients with advanced prostate cancer
    Yechen Wu, Xi Chen, Duocheng Qian, Wei Wang, Yiping Zhang, Jinxin Hu, Jun Zhu, Qiang Wu, Tinghu Cao
    BMC Urology.2021;[Epub]     CrossRef
  • Survival of women diagnosed with breast cancer and who have survived a previous cancer
    Sandi L. Pruitt, Hong Zhu, Daniel F. Heitjan, Asal Rahimi, Bhumika Maddineni, Anna Tavakkoli, Ethan A. Halm, David E. Gerber, Danyi Xiong, Caitlin C. Murphy
    Breast Cancer Research and Treatment.2021; 187(3): 853.     CrossRef
  • Trends in the proportion of second or later primaries among all newly diagnosed malignant cancers
    Chelsea Anderson, Deborah K. Mayer, Hazel B. Nichols
    Cancer.2021; 127(15): 2736.     CrossRef
  • Survival analysis of patients with primary breast duct carcinoma and lung adenocarcinoma: a population-based study from SEER
    Fengyuan Lv, Mingliang Cheng, Liang Jiang, Xiaoping Zhao
    Scientific Reports.2021;[Epub]     CrossRef
  • Research on Effectiveness of Prior Cancer on Survival Outcomes for Patients with Nonmetastatic Triple-Negative Breast Cancer: A Competing Risk Analysis and Propensity Score Matching Analysis of the SEER Database
    Heyan Chen, Lutong Yan, Shengyu Pu, Lizhe Zhu, Huimin Zhang, Can Zhou, Raffaele Palmirotta
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • Risk of breast cancer-related death in women with a prior cancer
    Fei Ji, Ci-Qiu Yang, Xiao-Ling Li, Liu-Lu Zhang, Mei Yang, Jie-Qing Li, Hong-Fei Gao, Teng Zhu, Min-Yi Cheng, Wei-Ping Li, Si-Yan Wu, Ai-Ling Zhong, Kun Wang
    Aging.2020; 12(7): 5894.     CrossRef
  • 8,106 View
  • 178 Download
  • 18 Web of Science
  • 15 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP